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A variant neoplastic line of human pluripotent stem cell (hPSC) displays unique tumorigenic
properties, including enhanced self-renewal and survival, and aberrant blockade in differentiation.
Sachlos et al. adopted a neoplastic hPSC differentiation platform to screen small molecules that
selectively induce differentiation of cancer stem cells.Recent studies support a hypothesis in
which subpopulations of tumor cells,
tumor initiating cells (TICs), drive tumori-
genesis and give rise to a large population
of differentiated progenies that make up
most of a tumor. Although conventional
chemotherapies reduce the bulk of the
tumor by effectively eliminating highly
proliferative cancer cells, refractory TICs
allow tumors to recur and thus account
for many treatment failures. The drug
resistance of TICs may be due to their
restricted cell cycle and quiescence;
higher expression of drug pumps; and/or
enhanced antioxidative, antiapoptotic,
DNA repair, and self-renewal mecha-
nisms, many of which are also shared by
tissue-specific normal stem cells. Conse-
quently, differentially targeting TICs, while
sparing normal stem cells, is a major
challenge. However, one strategy might
address that challenge. TICs with onco-
genic molecular alterations may be more
addicted to those above enhanced stemcell mechanisms and therefore targeting
such deregulation may sensitize TICs to
treatments (Frank et al., 2010). For
example, shifting enhanced self-renewal
to the normal level may effectively render
TICs more susceptible to conventional
therapy.
Several studies used chemical genetics
approaches tomodel the differentiation of
stem cells and TICs. Chemical libraries
were screened in hESCs (Desbordes
et al., 2008) or cancer cells with certain
stem-like properties (Gupta et al., 2009)
to identify compounds that maintain or
inhibit their self-renewal, providing tools
to interrogate underlying mechanisms.
However, drug discovery for differentially
targeting TICs (Shen et al., 2004) has
been hindered by difficulties in homoge-
nously expanding and maintaining rare
TICs in vitro (Figure 1A). This problemwas
addressed by developing specific condi-
tions for stably expanding certain subpop-
ulation of TICs (Pollard et al., 2009).In an interesting report published in this
issue of Cell, Sachlos et al. (2012) provide
another attractive approach. They interro-
gated neoplastic human pluripotent stem
cell (hPSC) as a human TIC surrogate for
high-content screening of differentiation
inducing agents (Figure 1B). Compounds
identified with this model were further
shown to selectively decrease the number
of human CD33+ hCD45+ acute myeloid
leukemia (AML) cells in a xenotransplanta-
tion model. This demonstrates the feasi-
bility of finding therapeutic candidates
for differentially targeting TIC differentia-
tion and therapeutic potentials of such
strategy for treating cancer.
Neoplastic hPSC is a culture-adapted
variant hESC line (Werbowetski-Ogilvie
et al., 2009) with subkaryotypic abnormal-
ities that exhibits acquired tumorigenic
features, including enhanced self-renewal
with reduced growth factor dependence
and blocked differentiation. Its FGFR1
and IGFR1 coexpression pattern is similar49, June 8, 2012 ª2012 Elsevier Inc. 1185
Figure 1. Strategies for Modeling TICs for Use in Drug Discovery
(A) TICs from in vivo niche are identified, isolated and stably expanded by defined in vitro culture.
(B) Clonal variant of normal hPSCs are stably expanded as neoplastic hPSCs exhibiting acquired
tumorigenic features.
(C) Nontumorigenic cancer cells can be reprogrammed into TICs or cancer cells with stem-like properties.
(D) Hypothesized tissue- and stage-specific nontumorigenic cancer cells with distinct genetic background
might be able to be reprogrammed by iPSC transcription factors into cancer-type specific neoplastic
hPSCs.to that of teratocarcinoma, and its derived
neural progenitors are tumorigenic in
recipient mice. These features support
its resemblance to TICs at the top of
tumor hierarchy, providing a basis as
a surrogate model to interrogate TIC
differentiation. Reporter lines of the
neoplastic hPSCs with transgenic Oct4-
GFP (as a pluripotency marker) were
generated and used in screening a known
drug library, where GFP intensity reflected
differentiation status. The confirmed hits
that significantly reduced GFP expression
were subsequently tested in normal
hESCs to further select compounds only
selectively and nontoxically inducing
neoplastic hPSC differentiation.
Among 26 hits identified from 2,446
compounds, thioridazine, a selective
dopamine receptor (DR) antagonist used
to treat the symptoms of schizophrenia,1186 Cell 149, June 8, 2012 ª2012 Elsevier Inwas further characterized. In functional
studies involving xenotransplantation of
leukemia stem cells from AML patient
samples, thioridazine treatment impaired
the leukemogenesis function of those
AML stem cells, while sparing the normal
hematopoietic stem/progenitor cells
(HSPCs). In contrast, salinomycin, an anti-
biotic that targets breast cancer stem
cells, significantly reduced hematopoietic
engraftment, indicating that the normal
HSPCs were impaired. Because many
TICs are quiescent and their initiated
differentiation may drive more active cell
cycling, a combination of thioridazine
and the antiproliferative AraC was further
demonstrated as a more effective treat-
ment in the AML model, supporting the
therapeutic potential of inducing TIC
differentiation. Interestingly, the study
suggested that thioridazine may exert itsc.effect by antagonizing D2-family DRs.
This is consistent with the observation
that male patients receiving DR antago-
nism treatment had a lower incidence of
rectum cancer and prostate cancer.
However, the mechanism by which DR
signaling regulates TIC self-renewal will
require further elucidation.
Although the use of neoplastic hPSC as
a TIC surrogate provides a useful
approach for identifying compounds with
selective differentiation inducing activity
on TICs, many challenges remain in anti-
cancer drug discovery. In various types
of tumors developed from distinct cells
of origin and microenvironments (niches)
through serial oncogenic, genetic, and
epigenetic changes, the deregulated
self-renewal ability of TICs strongly
depend on the context, and TICs (if they
exist) from different types of tumors at
different stages may rely on different
deregulated self-renewal mechanisms.
In addition, some tumor types do not
exclusively follow a TIC model (Shackle-
ton et al., 2009). Extrinsically, TICs are
regulated by a tumor-conferring niche
created by heterogeneous populations
of tumor and nontumor cells (Hanahan
and Weinberg, 2011). Thus, the self-
renewal mechanism involved in a niche-
dependent in vivo context of a primary
tumor might be fundamentally different
from the mechanism in a niche-indepen-
dent in vitro context. Therefore, future
challenges lie in establishing an anti-
cancer drug screening model that reca-
pitulates specific molecular alterations
under intrinsically and extrinsically speci-
fic contexts.
Despite these challenges, Sachlos and
colleagues’ work, together with recent
studies involving reprogramming nontu-
morigenic cancer cells to stem-like
cancer cells (Guo et al., 2012), provides
an innovative strategy for modeling TICs
(Figure 1C). These advances may also
lead to the possibility of generating
a neoplastic hPSC line for each tumor
type by the induced pluripotent stem cell
technology (Figure 1D). Thus, conceiv-
ably, the development of reprogrammed,
genetically distinct neoplastic hiPSC
models with an appropriate in vitro
niche interaction mechanism would
provide a context-specific drug discovery
platform for new cancer therapeutic
development.
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